Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanoform FinlandFRA:4YL -4.55%63 PB Ratio is 1.63 as of Jul. 15, 2026, which is 32% below its 10-year median of 2.38. GuruFocus rates FRA:4YL with a GF Score™ of 63/100 and a GF Value™ of €1.72 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Nanoform Finland ranks better than 69.14% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Nanoform Finland's share price is €0.756. Nanoform Finland's Book Value per Share for the quarter that ended in Mar. 2026 was €0.46. Hence, Nanoform Finland's PB Ratio of today is 1.63.
The historical rank and industry rank for Nanoform Finland's PB Ratio or its related term are showing as below:
FRA:4YL'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 2.38 Max: 81.82
Current: 1.58
During the past 10 years, Nanoform Finland's highest PB Ratio was 81.82. The lowest was 0.91. And the median was 2.38.
FRA:4YL's PB Ratio is ranked better than 69.14% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs FRA:4YL: 1.58
During the past 12 months, Nanoform Finland's average Book Value Per Share Growth Rate was -27.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -13.20% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Nanoform Finland was 145.20% per year. The lowest was -23.50% per year. And the median was -3.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nanoform Finland PB Ratio Related Terms
Nanoform Finland PB Ratio Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nanoform Finland's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nanoform Finland (FRA:4YL) has a PB Ratio of 1.63 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanoform Finland and its competitors. This is 32% below median its historical median of 2.38. Over the past decade, Nanoform Finland's PB Ratio has ranged from 0.91 to 81.82. According to the industry distribution chart, Nanoform Finland ranks #379 out of 1228 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Nanoform Finland's PB Ratio too high?
Nanoform Finland's current PB Ratio of 1.63 is 32% below median its 10-year median of 2.38. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 81.82. The Biotechnology industry median PB Ratio is 2.90. Nanoform Finland's value of 1.63 is 43.7% below this industry median. Based on the distribution chart, Nanoform Finland ranks #379 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #379 out of 1228 companies for PB Ratio. This puts Nanoform Finland in the upper half of its industry. The industry median PB Ratio is 2.90. Nanoform Finland's value of 1.63 is 43.7% below this benchmark. Historically, Nanoform Finland's own PB Ratio has ranged from 0.91 to 81.82 over the past decade. While the company's 10-year median is 2.38 vs. the industry median of 2.90, Nanoform Finland has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanoform Finland's current PB Ratio of 1.63 is 43.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanoform Finland and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanoform Finland's current PB Ratio is 1.63, which is 32% below median its own 10-year median of 2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (FRA:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.72, compared to a current price of €0.76 — trading 56% below its estimated fair value. The current PB Ratio is 1.63, which is 32% below median its 10-year median of 2.38 and 43.7% below the Biotechnology industry median of 2.90. Nanoform Finland's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nanoform Finland (FRA:4YL), the current PB Ratio is 1.63 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (FRA:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.76 is trading 56% below its estimated GF Value™ of €1.72.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for FRA:4YL:
PB Ratio: 1.63 (32% below median its 10-year median of 2.38)
GF Value™: €1.72 vs. price of €0.76 (56% below fair value)
Industry Position: 43.7% below the Biotechnology median (#379 of 1228)
No single metric tells the full story. See the FRA:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
63GF Score
Get the complete analysis for FRA:4YL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4YL has been successfully added to your 
